HRP20191248T1 - Kombinirana terapija za liječenje karcinoma jajnika - Google Patents
Kombinirana terapija za liječenje karcinoma jajnika Download PDFInfo
- Publication number
- HRP20191248T1 HRP20191248T1 HRP20191248TT HRP20191248T HRP20191248T1 HR P20191248 T1 HRP20191248 T1 HR P20191248T1 HR P20191248T T HRP20191248T T HR P20191248TT HR P20191248 T HRP20191248 T HR P20191248T HR P20191248 T1 HRP20191248 T1 HR P20191248T1
- Authority
- HR
- Croatia
- Prior art keywords
- bevacizumab
- patient
- platinum
- use according
- resistant
- Prior art date
Links
- 206010033128 Ovarian cancer Diseases 0.000 title claims 6
- 238000011282 treatment Methods 0.000 title claims 4
- 206010061535 Ovarian neoplasm Diseases 0.000 title claims 2
- 238000002648 combination therapy Methods 0.000 title 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 20
- 229960000397 bevacizumab Drugs 0.000 claims 13
- 229910052697 platinum Inorganic materials 0.000 claims 10
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims 4
- 229930012538 Paclitaxel Natural products 0.000 claims 4
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 claims 4
- 229960001592 paclitaxel Drugs 0.000 claims 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 4
- 201000001342 Fallopian tube cancer Diseases 0.000 claims 3
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 206010003445 Ascites Diseases 0.000 claims 1
- 230000003187 abdominal effect Effects 0.000 claims 1
- 238000011394 anticancer treatment Methods 0.000 claims 1
- 201000001343 fallopian tube carcinoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000002524 peritoneal carcinoma Diseases 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q30/00—Commerce
- G06Q30/02—Marketing; Price estimation or determination; Fundraising
- G06Q30/0241—Advertisements
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q90/00—Systems or methods specially adapted for administrative, commercial, financial, managerial or supervisory purposes, not involving significant data processing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Claims (10)
1. Bevacizumab, naznačen time, da je za uporabu u postupku liječenja pacijentice kojoj je dijagnosticiran epitelni karcinom jajnika rezistentan na platinu (EOC), karcinom Fallopijevih cijevi rezistentan na platinu (FTC) ili primarni peritonealni karcinom rezistentan na platinu (PPC), pri čemu postupak obuhvaća primjenu učinkovite doze bevacizumaba i paklitaksela spomenutoj pacijentici, gdje je spomenuta pacijentica primila dva režima liječenja protiv karcinoma ili manje od toga, dok spomenuti tretman produljuje preživljenje bez napredovanja bolesti za spomenutu pacijenticu u usporedbi s pacijenticom koja ima epitelni karcinom jajnika rezistentan na platinu (EOC), karcinom Fallopijevih cijevi rezistentan na platinu (FTC) ili primarni peritonealni karcinom rezistentan na platinu (PPC), a koja prima samo paklitaksel.
2. Bevacizumab za uporabu prema patentnom zahtjevu 1, naznačen time, da spomenuta pacijentica nije refraktarna na prethodnu terapiju platinom.
3. Bevacizumab za uporabu prema patentnom zahtjevu 1, naznačen time, da spomenuta pacijentica ima bolest mjerljivu prema RECIST 1.0 ili bolest procjenjivu prema CA-125 prema GCIG kriterijima.
4. Bevacizumab za uporabu prema patentnom zahtjevu 1, naznačen time, da spomenuta pacijentica ima status ECOG performansa od 0 do 2 te životni vijek od barem 12 tjedana.
5. Bevacizumab za uporabu prema patentnom zahtjevu 1, naznačen time, da se spomenuta učinkovita količina paklitaksela primjenjuje pri dozi od 80 mg/m2 kao jednosatna infuzija na dane 1, 8, 15 i 22, svaka 4 tjedna.
6. Bevacizumab za uporabu prema patentnom zahtjevu 1, naznačen time, da je učinkovita količina bevacizumaba 10 mg/kg intravenski svaka dva tjedna ili 15 mg/kg intravenski svaka tri tjedna.
7. Bevacizumab za uporabu prema patentnom zahtjevu 6, naznačen time, da se učinkovita količina bevacizumaba početno daje intravenski tijekom 90 minuta s posljedičnim infuzijama tijekom 60 minuta, a potom 30 minuta.
8. Bevacizumab za uporabu prema patentnom zahtjevu 1, naznačen time, da spomenuta pacijentica ima razdoblje bez primanja platine (PFI - eng. Platinum free interval) kraće od 3 mjeseca.
9. Bevacizumab za uporabu prema patentnom zahtjevu 1, naznačen time, da spomenuta pacijentica ima abdominalni ascites.
10. Bevacizumab za uporabu prema patentnom zahtjevu 1, naznačen time, da spomenuti tretman poboljšava objektivnu stopu odgovora spomenute pacijentice (ORR – eng. objective response rate) u usporedbi s pacijenticom koja ima karcinom jajnika otporan na platinu, a koja prima samo paklitaksel.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261610128P | 2012-03-13 | 2012-03-13 | |
| US201261653598P | 2012-05-31 | 2012-05-31 | |
| US201261672987P | 2012-07-18 | 2012-07-18 | |
| PCT/EP2013/054818 WO2013135602A2 (en) | 2012-03-13 | 2013-03-11 | Combination therapy for the treatment of ovarian cancer |
| EP13708435.6A EP2825558B1 (en) | 2012-03-13 | 2013-03-11 | Combination therapy for the treatment of ovarian cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191248T1 true HRP20191248T1 (hr) | 2019-10-18 |
Family
ID=47844333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191248TT HRP20191248T1 (hr) | 2012-03-13 | 2019-07-11 | Kombinirana terapija za liječenje karcinoma jajnika |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US20150098988A1 (hr) |
| EP (2) | EP2825558B1 (hr) |
| JP (2) | JP6563197B2 (hr) |
| KR (1) | KR102082363B1 (hr) |
| CN (1) | CN104334577A (hr) |
| AR (1) | AR090313A1 (hr) |
| AU (2) | AU2013231410B2 (hr) |
| BR (1) | BR112014018964A2 (hr) |
| CA (2) | CA3056813A1 (hr) |
| CO (1) | CO7000770A2 (hr) |
| CR (1) | CR20140400A (hr) |
| CY (1) | CY1121821T1 (hr) |
| DK (1) | DK2825558T3 (hr) |
| EA (1) | EA201400996A1 (hr) |
| ES (1) | ES2736030T3 (hr) |
| HK (1) | HK1202122A1 (hr) |
| HR (1) | HRP20191248T1 (hr) |
| HU (1) | HUE045445T2 (hr) |
| IL (2) | IL234174B (hr) |
| LT (1) | LT2825558T (hr) |
| MX (1) | MX365139B (hr) |
| PE (1) | PE20141909A1 (hr) |
| PH (1) | PH12014501543A1 (hr) |
| PL (1) | PL2825558T3 (hr) |
| PT (1) | PT2825558T (hr) |
| RS (1) | RS58964B1 (hr) |
| SG (1) | SG11201404417PA (hr) |
| SI (1) | SI2825558T1 (hr) |
| TW (1) | TW201343178A (hr) |
| WO (1) | WO2013135602A2 (hr) |
| ZA (1) | ZA201404843B (hr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE042192T2 (hu) | 2011-09-23 | 2019-06-28 | Oncomed Pharm Inc | VEGF/DLL4-kötõ ágensek és alkalmazásaik |
| EP2825558B1 (en) | 2012-03-13 | 2019-05-15 | F.Hoffmann-La Roche Ag | Combination therapy for the treatment of ovarian cancer |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| JP6967003B2 (ja) * | 2015-09-23 | 2021-11-17 | メレオ バイオファーマ ５ インコーポレイテッド | がんの処置のための方法および組成物 |
| KR20180104635A (ko) | 2015-12-30 | 2018-09-21 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| WO2019005754A1 (en) * | 2017-06-26 | 2019-01-03 | The Cleveland Clinic Foundation | TREATMENT AGAINST CANCER |
| CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
| CN115814076A (zh) * | 2021-07-01 | 2023-03-21 | 江苏先声药业有限公司 | 抗人vegf抗体与化药联用在制备治疗卵巢癌的药物中的应用 |
| CN117940164A (zh) * | 2022-04-26 | 2024-04-26 | 石药集团中奇制药技术（石家庄）有限公司 | 米托蒽醌脂质体联合抗血管生成靶向药治疗卵巢癌的用途 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| EP0564531B1 (en) | 1990-12-03 | 1998-03-25 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| US20030206899A1 (en) | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| ATE348110T1 (de) | 1992-10-28 | 2007-01-15 | Genentech Inc | Hvegf rezeptor als vegf antagonist |
| US5635388A (en) | 1994-04-04 | 1997-06-03 | Genentech, Inc. | Agonist antibodies against the flk2/flt3 receptor and uses thereof |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| CA2226575C (en) | 1995-07-27 | 2011-10-18 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
| US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| US20070059302A1 (en) | 1997-04-07 | 2007-03-15 | Genentech, Inc. | Anti-vegf antibodies |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| PT1787999E (pt) | 1997-04-07 | 2010-11-11 | Genentech Inc | Anticorpos anti-vegf |
| DE69829891T2 (de) | 1997-04-07 | 2005-10-06 | Genentech, Inc., South San Francisco | Anti-VEGF Antikörper |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| BR9813365A (pt) | 1997-12-05 | 2004-06-15 | Scripps Research Inst | Método para produção e humanização de um anticorpo monoclonal de rato |
| DE69926536T3 (de) | 1998-12-22 | 2013-09-12 | Genentech, Inc. | Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung |
| US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
| CA2393869A1 (en) | 1999-12-15 | 2001-06-21 | Genetech,Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| ATE378403T1 (de) | 2000-11-30 | 2007-11-15 | Medarex Inc | Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern |
| IL149701A0 (en) | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
| JP4753578B2 (ja) | 2002-06-03 | 2011-08-24 | ジェネンテック， インコーポレイテッド | 合成抗体ファージライブラリー |
| WO2004065416A2 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
| ME00425B (me) | 2003-05-30 | 2011-10-10 | Genentech Inc | Liječenje sa anti-vegf antitijelima |
| US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
| RU2386638C2 (ru) | 2004-03-31 | 2010-04-20 | Дженентек, Инк. | Гуманизированные анти-тфр-бета-антитела |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| SV2006002143A (es) * | 2004-06-16 | 2006-01-26 | Genentech Inc | Uso de un anticuerpo para el tratamiento del cancer resistente al platino |
| US20060009360A1 (en) | 2004-06-25 | 2006-01-12 | Robert Pifer | New adjuvant composition |
| SI3530673T1 (sl) | 2004-09-03 | 2022-08-31 | Genentech, Inc. | Humanizirani antagonisti proti beta7 in njihove uporabe |
| US20070166388A1 (en) | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| WO2007056441A2 (en) | 2005-11-07 | 2007-05-18 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
| WO2007064919A2 (en) | 2005-12-02 | 2007-06-07 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| AU2007249408A1 (en) | 2006-05-09 | 2007-11-22 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
| AU2007335744A1 (en) * | 2006-12-20 | 2008-06-26 | Alberto A. Gabizon | Method for administration of pegylated liposomal doxorubicin |
| CA2675451A1 (en) | 2007-02-01 | 2008-07-08 | Genentech, Inc. | Combination therapy with angiogenesis inhibitors |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| WO2009149150A2 (en) * | 2008-06-03 | 2009-12-10 | Alza Corporation | Composition comprising liposome-entrapped doxorubicin and methods of administration |
| JP6041489B2 (ja) | 2008-11-22 | 2016-12-07 | ジェネンテック， インコーポレイテッド | 乳癌の治療のための化学療法と併用した抗ｖｅｇｆ抗体の使用 |
| US20190185555A1 (en) | 2017-12-19 | 2019-06-20 | Genentech, Inc. | Anti-angiogenesis therapy for the treatment of previously treated breast cancer |
| EP3064509A3 (en) * | 2010-02-23 | 2016-11-02 | F. Hoffmann-La Roche AG | Anti-angiogenesis therapy for the treatment of ovarian cancer |
| EP2825558B1 (en) | 2012-03-13 | 2019-05-15 | F.Hoffmann-La Roche Ag | Combination therapy for the treatment of ovarian cancer |
-
2013
- 2013-03-11 EP EP13708435.6A patent/EP2825558B1/en active Active
- 2013-03-11 LT LTEP13708435.6T patent/LT2825558T/lt unknown
- 2013-03-11 HU HUE13708435A patent/HUE045445T2/hu unknown
- 2013-03-11 CA CA3056813A patent/CA3056813A1/en not_active Abandoned
- 2013-03-11 CN CN201380024869.3A patent/CN104334577A/zh active Pending
- 2013-03-11 CA CA2860941A patent/CA2860941C/en active Active
- 2013-03-11 BR BR112014018964-1A patent/BR112014018964A2/pt not_active Application Discontinuation
- 2013-03-11 EP EP19174209.7A patent/EP3553083A1/en active Pending
- 2013-03-11 MX MX2014010591A patent/MX365139B/es active IP Right Grant
- 2013-03-11 ES ES13708435T patent/ES2736030T3/es active Active
- 2013-03-11 SG SG11201404417PA patent/SG11201404417PA/en unknown
- 2013-03-11 PL PL13708435T patent/PL2825558T3/pl unknown
- 2013-03-11 PE PE2014001409A patent/PE20141909A1/es not_active Application Discontinuation
- 2013-03-11 SI SI201331522T patent/SI2825558T1/sl unknown
- 2013-03-11 PT PT13708435T patent/PT2825558T/pt unknown
- 2013-03-11 RS RS20190846A patent/RS58964B1/sr unknown
- 2013-03-11 KR KR1020147024773A patent/KR102082363B1/ko active IP Right Review Request
- 2013-03-11 DK DK13708435.6T patent/DK2825558T3/da active
- 2013-03-11 US US14/384,863 patent/US20150098988A1/en not_active Abandoned
- 2013-03-11 EA EA201400996A patent/EA201400996A1/ru unknown
- 2013-03-11 JP JP2014561385A patent/JP6563197B2/ja active Active
- 2013-03-11 AU AU2013231410A patent/AU2013231410B2/en active Active
- 2013-03-11 WO PCT/EP2013/054818 patent/WO2013135602A2/en active Application Filing
- 2013-03-12 AR ARP130100793 patent/AR090313A1/es unknown
- 2013-03-12 TW TW102108775A patent/TW201343178A/zh unknown
-
2014
- 2014-06-27 CO CO14139058A patent/CO7000770A2/es not_active Application Discontinuation
- 2014-06-30 ZA ZA2014/04843A patent/ZA201404843B/en unknown
- 2014-07-03 PH PH12014501543A patent/PH12014501543A1/en unknown
- 2014-08-18 IL IL234174A patent/IL234174B/en active IP Right Grant
- 2014-08-26 CR CR20140400A patent/CR20140400A/es unknown
-
2015
- 2015-03-11 HK HK15102494.0A patent/HK1202122A1/xx unknown
-
2016
- 2016-05-12 US US15/153,637 patent/US11384142B2/en active Active
-
2017
- 2017-11-10 AU AU2017258927A patent/AU2017258927A1/en not_active Abandoned
-
2018
- 2018-07-13 JP JP2018132869A patent/JP6640288B2/ja active Active
- 2018-12-18 IL IL263781A patent/IL263781A/en unknown
-
2019
- 2019-07-11 HR HRP20191248TT patent/HRP20191248T1/hr unknown
- 2019-07-16 CY CY20191100758T patent/CY1121821T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191248T1 (hr) | Kombinirana terapija za liječenje karcinoma jajnika | |
| EA201401028A1 (ru) | Фармацевтическая композиция, содержащая эмпаглифлозин и лекарственное средство от ожирения | |
| BR112015024678A2 (pt) | inibidor da cinase | |
| BR112014000380A2 (pt) | composição farmacêutica, métodos para tratamento e usos dos mesmos | |
| WO2015123576A3 (en) | Targeted nanoparticle compositions and methods of their use to treat obesity | |
| MX2016011333A (es) | Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. | |
| WO2014058979A3 (en) | Laquinimod for reducing thalamic damage in multiple sclerosis | |
| NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
| RU2015145997A (ru) | Противоопухолевое лекарственное средство, включающее низкодозированный гидрохлорида иринотекана гидрат | |
| BR112014014814A8 (pt) | dispositivo médico | |
| HRP20230523T1 (hr) | Antitumorski agens i sredstvo za poboljšavanje antitumorskog efekta | |
| UY35771A (es) | Tienouracil-carboxamidas cíclicas y su uso | |
| Rino et al. | Phase II study on the combination of irinotecan plus cisplatin as a second‑line therapy in patients with advanced or recurrent gastric cancer | |
| Siddall et al. | The pain book: finding hope when it hurts | |
| RU2011101481A (ru) | Способ профилактики острой декомпрессионной болезни | |
| TH137483A (th) | การรักษาโดยการยับยั้งการเกิดเส้นเลือดใหม่ (anti-angiogenesis therapy) สำหรับบำบัดมะเร็งรังไข่ (ovarian cancer) | |
| RU2012142070A (ru) | Способ восстановительного лечения больных хроническим панкреатитом у работников с вредными условиями труда | |
| Samarghandian et al. | Caspase-dependent pathway in apoptosis induced by Safranal in alveolar human lung cancer cell line | |
| Uusitalo et al. | A grey keratinous tarsal cyst with Gram+ cocci. | |
| TH137483B (th) | การรักษาโดยการยับยั้งการเกิดเส้นเลือดใหม่ (anti-angiogenesis therapy) สำหรับบำบัดมะเร็งรังไข่ (ovarian cancer) | |
| 袁嘉敏 | Impact of lymphocytes subgroups in peripheral blood on survival rate of patients with gastric cancer | |
| Mouri et al. | C40 PIERCING THE DARK: ILLUMINATING THE CLINICAL AND BIOLOGICAL CHARACTERISTICS OF LUNG CANCER: Bevacizumab, When Added To Pemetrexed/platinum, Prolongs Survival In Previously Untreated Patients With Advanced Non-Squamous Non-Small-Cell Lung Cancer In Japan | |
| PL408781A1 (pl) | Zastosowanie nanocząstek metalicznej platyny | |
| Zhong | Carboplatin/irinotecan | |
| Saad et al. | EFFECTS OF LONG-TERM TESTOSTERONE UNDECANOATE (TU) THERAPY ON ANTHROPOMETRIC PARAMETERS IN HYPOGONADAL MEN WITH TYPE 2 DIABETES (T2DM): REAL-LIFE DATA FROM A REGISTRY STUDY |